These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25691509)

  • 1. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy.
    Chen MH; Chen MH; Tsai CY; Chou CT; Lin HY; Huang DF; Huang YH
    Lupus; 2015 Sep; 24(10):1029-36. PubMed ID: 25691509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
    Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
    Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
    Colson P; Bregigeon S; Tourres C; Solas C; Poizot-Martin I; Tamalet C
    J Clin Virol; 2013 Sep; 58(1):309-14. PubMed ID: 23810614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response].
    Cheng ML; Wang J; Zeng AP; Liu XF
    Zhonghua Nei Ke Za Zhi; 2012 Oct; 51(10):751-4. PubMed ID: 23290969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection.
    Castillo I; Bartolomé J; Quiroga JA; Barril G; Carreño V
    Aliment Pharmacol Ther; 2009 Sep; 30(5):477-86. PubMed ID: 19523175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
    Hsu WF; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Tsai PC; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    Sci Rep; 2020 Mar; 10(1):5372. PubMed ID: 32214132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.
    Lee HL; Bae SH; Jang B; Hwang S; Yang H; Nam HC; Sung PS; Lee SW; Jang JW; Choi JY; Han NI; Song BJ; Lee JW; Yoon SK
    Gut Liver; 2017 Nov; 11(6):870-877. PubMed ID: 28750484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response.
    Lin A; Thadareddy A; Goldstein MJ; Lake-Bakaar G
    J Med Virol; 2008 Oct; 80(10):1720-2. PubMed ID: 18712814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
    Kunimoto H; Ikeda K; Sorin Y; Fujiyama S; Kawamura Y; Kobayashi M; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2016; 90(3):167-75. PubMed ID: 26901157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C reinfection after sustained virological response.
    Midgard H; Bjøro B; Mæland A; Konopski Z; Kileng H; Damås JK; Paulsen J; Heggelund L; Sandvei PK; Ringstad JO; Karlsen LN; Stene-Johansen K; Pettersson JH; Dorenberg DH; Dalgard O
    J Hepatol; 2016 May; 64(5):1020-1026. PubMed ID: 26780289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study.
    Lin WT; Chen YM; Chen DY; Lan JL; Chang CS; Yeh HZ; Yang SS
    Lupus; 2018 Jan; 27(1):66-75. PubMed ID: 28534427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?
    Hara K; Rivera MM; Koh C; Demino M; Page S; Nagabhyru PR; Rehermann B; Liang TJ; Hoofnagle JH; Heller T
    J Infect Dis; 2014 Jan; 209(1):38-45. PubMed ID: 24127561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus.
    Chen MH; Wu CS; Chen MH; Tsai CY; Lee FY; Huang YH
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.
    Thomas HC; Török ME; Forton DM; Taylor-Robinson SD
    J Hepatol; 1999; 31 Suppl 1():152-9. PubMed ID: 10622579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.